Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
21 Jan 2025
bởiAudrey Abella
In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).
